FLAGSTAFF, Ariz., April 24, 2019 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES), a developer of proprietary technologies for managing animal pest populations through fertility control, announces that AB1788, which would ban the use of Second Generation Anticoagulant Rodenticides (SGARs) has moved another step closer to becoming law.

California is poised to create the California Ecosystems Protection Act of 2019 which would prohibit the use of the four major Second Generation Anticoagulant Rodenticides (SGARs) commonly used in rodent pest control.  The target problem being addressed in this bill is the vulnerability of wildlife to the lethality and ecologic persistence of these SGARs used for rodent control, that have long-term health impacts on non-target species such as birds of prey, mountain lions, bobcats, fishers, and endangered species. 

"It is becoming clear to us that within the State of California, the demand for more ecologically sensitive products continues to grow and it is not a question of 'if,' it is a question of 'when' this legislation becomes law. The professional pest managers in the State can bridge this transition by adding ContraPest, our fertility control flagship product, to their integrated pest management solution strategies," said Dr. Loretta Mayer, CEO and co-Founder of SenesTech.

"Meeting the demands of the fifth largest economy in the world is a challenge that I welcome," said Senior Vice President of Commercialization, Ed Albe. "ContraPest is the right product, in the right place, at the right time. That is why we have chosen to invest our resources into assuring that Californian's have an alternative solution for this inevitable event."

The next step for this bill is to go to the California Senate for approval and ultimately to Governor Newsome for signature.  As this process moves forward SenesTech will continue to serve the wildlife, citizens and environment of California. 

About SenesTech 

SenesTech is changing the paradigm of pest management by targeting the root cause of the problem: reproduction.

ContraPest^® is an innovative technology with an approach that targets the reproductive capabilities of both sexes in rat populations, inducing egg loss in female rats and impairing sperm development in males. Using a proprietary bait delivery method, ContraPest^® is dispensed in a highly palatable liquid formulation that promotes sustained consumption by rat communities. ContraPest^® is designed, formulated and dispensed to be low hazard for handlers and non-target species such as wildlife, livestock and pets, where the active ingredients break down rapidly.

We believe ContraPest^® will establish a new paradigm in rodent control, resulting in a decreased reliance on lethal options. For more information visit the SenesTech website at www.senestech.com.

Safe Harbor Statement

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors and other risks identified in our filings with the Securities and Exchange Commission. Forward looking statements include, but are not limited to, our expectation regarding sales commitments, our expectation regarding the conversion of sales commitments and programs to revenue, our belief that our product is more humane, less harmful to the environment and more effective than traditional methods, and our belief that ContraPest will establish a new paradigm in rodent control without environmental effects of rodenticides.  All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

CONTACT: 

Investor: Robert Blum, Joe Dorame, Joe Diaz, Lytham Partners, LLC, 602-889-9700, senestech@lythampartners.com

Company: Tom Chesterman, Chief Financial Officer, SenesTech, Inc., 928-779-4143

SOURCE SenesTech, Inc.